Basic Search
|
Summaries
|
Advanced Search
Violation Tracker Current Parent Company Summary
Current Parent Company Name: Bristol-Myers Squibb
Ownership Structure: publicly traded (ticker symbol BMY)
Headquartered in: New York
Major Industry: pharmaceuticals
Specific Industry: pharmaceuticals
Penalty total since 2000: $2,617,149,410
Number of records: 51
| Top 5 Offense Groups (Groups Defined) | Penalty Total | Number of Records |
| competition-related offenses | $956,331,200 | 17 |
| healthcare-related offenses | $534,500,000 | 3 |
| government-contracting-related offenses | $470,338,719 | 7 |
| safety-related offenses | $459,086,655 | 3 |
| financial offenses | $150,006,600 | 2 |
| Top 5 Primary Offense Types | Penalty Total | Number of Records |
| price-fixing or anti-competitive practices | $612,315,000 | 13 |
| off-label or unapproved promotion of medical products | $534,500,000 | 3 |
| False Claims Act and related | $470,338,719 | 7 |
| product safety violation | $458,006,000 | 1 |
| fraud | $300,000,000 | 1 |
Notes: Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the
Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
Links: For a summary of this company's regulatory penalties in more than 50 other countries, see its Violation Tracker Global summary page
here.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found
here.
Individual Penalty Records:
Click on the company or penalty amount for more information on each case.
| Company | Primary Offense Type | Year | Agency | Penalty Amount  |
| Bristol-Myers Squibb Company | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
| Bristol-Myers Squibb Company et al. | product safety violation | 2024 | HI-AG | $458,006,000 |
| Bristol-Myers Squibb | fraud | 2005 | USAO | $300,000,000 |
| Celgene Corp. | False Claims Act and related | 2017 | USAO | $280,000,000 |
| Bristol-Myers Squibb Company | price-fixing or anti-competitive practices | 2003 | private lawsuit-federal | $220,000,000 |
| Bristol-Myers Squibb | False Claims Act and related | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $187,000,000 |
| Bristol-Myers Squibb Company | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
| Bristol-Myers Squibb Co. | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $100,000,000 |
| Bristol-Myers Squibb | False Claims Act and related | 2021 | USAO | $75,000,000 |
| Bristol Myers Squibb Co. | False Claims Act and related | 2021 | MULTI-AG | $75,000,000 |
| Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2003 | private lawsuit-federal | $65,000,000 |
| Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $55,000,000 |
| Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2004 | private lawsuit-federal | $50,000,000 |
| DuPont Pharmaceuticals Company | price-fixing or anti-competitive practices | 2002 | private lawsuit-federal | $44,500,000 |
| Briston-Myers Squibb | benefit plan administrator violation | 2005 | private lawsuit-federal | $41,220,000 |
| Celgene Corporation | price-fixing or anti-competitive practices | 2020 | private lawsuit-federal | $34,000,000 |
| Bristol-Myers Squibb | kickbacks and bribery | 2016 | CA-INS | $30,000,000 |
| Bristol-Myers Squibb | False Claims Act and related | 2010 | PA-AG | $27,600,000 |
| Celgene Corp. | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
| Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
| Bristol-Myers Squibb Co. | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $19,000,000 |
| Bristol-Myers Squibb | Foreign Corrupt Practices Act | 2015 | SEC | $14,000,000 |
| Bristol-Myers Squibb | False Claims Act and related | 2008 | AL-AG | $11,000,000 |
| Bristol-Myers Squibb | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $10,800,000 |
| Bristol-Myers Squibb Co. | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $10,000,000 |
| Bristol-Myers Squibb | air pollution violation | 2008 | EPA | $3,650,000 |
| Bristol-Myers Squibb | environmental violation | 2009 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,328,154 |
| Bristol-Myers Squibb Company | price-fixing or anti-competitive practices | 2009 | FTC | $2,100,000 |
| Bristol-Myers Squibb Company and Apothecon, Inc. | False Claims Act and related | 2008 | ID-AG | $1,738,719 |
| Bristol-Myers Squibb Company | consumer protection violation | 2019 | WV-AG | $1,600,000 |
| Bristol-Myers Squibb Company | price-fixing or anti-competitive practices | 2008 | MULTI-AG | $1,100,000 |
| Bristol-Myers Squibb | drug or medical equipment safety violation | 2007 | DOJ_ANTITRUST | $1,000,000 |
| American BioScience Inc. | price-fixing or anti-competitive practices | 2003 | private lawsuit-federal | $815,000 |
| American Pharmaceutical Partners, Inc. | wage and hour violation | 2004 | WHD | $160,203 |
| BRISTOL-MYERS SQUIBB COMPANY | workplace safety or health violation | 2023 | OSHA | $80,655 |
| Bristol Myers Squibb Company | environmental violation | 2008 | EPA | $66,770 |
| Bristol Myers Squibb Manufacturing Company | environmental violation | 2008 | EPA | $52,000 |
| BRISTOL-MYERS SQUIBB CO | air pollution violation | 2003 | NJ-ENV | $28,000 |
| Bristol-Myers Squibb Company | environmental violation | 2011 | CT-ENV | $20,000 |
| BRISTOL - MYERS SQUIBB MEDICAL IMAGING INC | environmental violation | 2009 | EPA | $19,538 |
| Bristol-Myers Squibb Medical Imaging, Inc. | export control violation | 2004 | BIS | $16,200 |
| BRISTOL MYERS SQUIBB CO | hazardous waste violation | 2005 | NJ-ENV | $12,000 |
| BRISTOL-MYERS SQUIBB | environmental violation | 2023 | MA-ENV | $11,615 |
| E.R. SQUIBB & SONS | solid waste violation | 2009 | NJ-ENV | $10,000 |
| E.R. Squibb & Sons LLC | environmental violation | 2009 | EPA | $8,125 |
| DuPont Pharmaceuticals Company | economic sanction violation | 2004 | OFAC | $6,600 |
| Celgene Corporation | environmental violation | 2013 | EPA | $6,035 |
| BRISTOL-MYERS SQUIBB CO | air pollution violation | 2001 | NJ-ENV | $6,000 |
| E R SQUIBB & SONS LLC | air pollution violation | 2013 | NJ-ENV | $5,950 |
| Abraxis Bioscience, Inc. | air pollution violation | 2012 | CA-SCAQMD | $5,000 |
| BRISTOL-MYERS SQUIBB COMPANY | environmental violation | 2000 | EPA | $5,000 |
